Navigation Links
Grant to help researchers find leukemia's hiding places
Date:2/6/2014

GAINESVILLE, Fla. In scary movies, the killer often comes back to life mysteriously, attacking again when the main character least expects it. Blood cancers are like this too, finding a safe spot to hide during treatment and then striking again when a patient is in remission.

The return of a blood cancer, such as leukemia, after treatment is one of the biggest challenges patients and physicians face, which is why University of Florida Health researcher Christopher Cogle, M.D., is leading a research effort to root these cancer cells out of their hiding spots and kill them.

The Leukemia and Lymphoma Society recently awarded Cogle and his team a two-year, $800,000 grant to find compounds that interfere with cancer cells' ability to go into hiding. Cogle was one of 14 researchers in the United States to receive funding through the society's Quest for Cures program.

"We will look for compounds that interrupt the binding of blood cancer cells to blood vessels," said Cogle. "Recently we found that blood vessels are safe havens for leukemia cells and that targeting these sanctuaries makes the leukemia cells more susceptible to chemotherapy. A major goal of my research group is to make blood cancers more vulnerable to treatment by evicting them from their hiding spots."

In 2013, 48,610 patients were diagnosed with leukemia and nearly 24,000 people died from the disease, according to the American Cancer Society. About half of adult patients who go into remission after treatment for acute leukemias will eventually relapse.

The researchers are initially focusing on blood vessels because they run in and out of the bone into the spongy inner layer of the bone marrow, forming several cozy spots for cancer cells to lie in wait.

"In the big picture, this is just one part of the microenvironment for cancer cells," Cogle said. "We will move on to other parts. Early results from our research group show that the inner bone lini
'/>"/>

Contact: April Frawley
afrawley@ufl.edu
352-273-5817
University of Florida
Source:Eurekalert

Page: 1 2

Related biology news :

1. A fragrant new biofuel
2. Record-breaking grant: New research project to investigate the causes of mental disorders
3. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
4. ASBMB wins National Science Foundation grant to enhance K-12 science education
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers
7. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
8. UC Riverside receives grant for global health and development research
9. Biology professor secures grant to save West Virginias primary natural history collection
10. Lawson recieves Grand Challenges Explorations grant for groundbreaking research
11. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Chinese on EurekAlert! Chinese . An ... Vinatzer and Giorgio Balestra of the University of Tuscia in ... a devastating pathogen back to its likely origin. ... ) has been threatening the world,s kiwifruit industry and destroying ...
... natural habitat in farming areas that supports ladybugs could help ... help farmers reduce their costs, says a Michigan State University ... saving farmers an estimated $4.6 billion a year on insecticides. ... helping them to survive and thrive in areas where they ...
... announced today that it is a Grand Challenges Explorations winner, ... Dr. Gregor Reid and his team are the first ... The research project will study the impact of ... on the health outcomes of pregnant women and their children. ...
Cached Biology News:Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium 2Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium 3Increasing predator-friendly land can help farmers reduce costs 2Lawson recieves Grand Challenges Explorations grant for groundbreaking research 2
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Outlines Ambitious Growth Plans, Technology Leadership, INDIANAPOLIS, ... AgroSciences, a wholly owned subsidiary of The Dow ... of a presentation made to investors,earlier today by ... was speaking at the Goldman Sachs Agricultural Chemicals,Conference ...
... February 12, Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: ... earnings on Thursday 21 February 2008., Results ... 12:00 GMT / 07:00 EST Investor meeting and ... Investor & Analyst meeting and conference call:, ...
... Healthcare Clients Throughout a ... Product,s Lifecycle, NEW ... Maryland-based MMG, an industry leader in patient,enrollment for clinical trials, will ... group. With this partnership, Ketchum,will greatly expand the depth of services ...
Cached Biology Technology:Dow AgroSciences' Success Presented to Wall Street 2Full Year 2007 Results Date Notification - 21 February 2008 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 3Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 4
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: